HUH, what qualified accountant would EVER talk about CFP by excluding any cash expenses? Oh and by the way, over 20m of the loss was non cash ie accounting for derivative liabilities. Under water? hysterically funny and not true aby any stretch of the imagination.
It just shows they know nothing about what they are talking about. They don't realize the type of drugs already being prescribed. OxyContin has 80 mg and Opana comes stronger WITHOUT the tamper resistant formulation.
Plus, Purdue has NOT had theirs even approved yet. Zogenix most likely will have their drug approved at same time.
Do you have any idea the amount of lawsuits Zogenix is about to win? How many doctors should lose their ability to practice medicine because they can't even use a simple drug comparison chart?
This company is fine. Zohydro is pennies compared to Relday. Relday is finishing Phase 1 clinical trials and will be set to launch in 2016.
FDA made Zohydro go through thorough 18 month review process that has been repetitively and publicly been reaffirmed. Zogenix has license to the IP around Zohydro, AND the abuse deterrent formulation in development. IP alone is worth tens of millions
News 
Market Data 
Discover 
